Evidence map›Paper›PMID 26708452›Full record

ArticleNeurochemical research2016

Hydrogen Sulfide Selectively Inhibits γ-Secretase Activity and Decreases Mitochondrial Aβ Production in Neurons from APP/PS1 Transgenic Mice.

Feng-Li Zhao, Pei-Feng Qiao, Ning Yan, Dan Gao, Meng-Jie Liu, Yong Yan

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Advances of HAntioxidants (Basel, Switzerland) · 2023
    Review
  5. Article
  6. Hydrogen Sulfide (HCurrent neuropharmacology · 2022
    Review
  7. Sulfur-containing therapeutics in the treatment of Alzheimer's disease.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2021
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Feng-Li ZhaoExperimental Research Center, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, No. 1 Youyi Road, Chongqing, 400016, China.
Pei-Feng QiaoExperimental Research Center, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, No. 1 Youyi Road, Chongqing, 400016, China.
Ning YanDepartment of Neurology, The University-Town Hospital of Chongqing Medical University, Chongqing, China.
Dan GaoExperimental Research Center, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, No. 1 Youyi Road, Chongqing, 400016, China.
Meng-Jie LiuExperimental Research Center, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, No. 1 Youyi Road, Chongqing, 400016, China.
Yong YanExperimental Research Center, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, No. 1 Youyi Road, Chongqing, 400016, China. yanyongzflh@163.com.
Chongqing Medical University · CNFirst Affiliated Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydrogen sulfide (H2S) is now considered to be a gasotransmitter and may be involved in the pathological process of Alzheimer's disease (AD). A majority of APP is associated with mitochondria and is a substrate for the mitochondrial γ-secretase. The mitochondria-associated APP metabolism where APP intracellular domains (AICD) and Aβ are generated locally and may contribute to mitochondrial dysfunction in AD. Here, we aimed to investigate the ability of H2S to mediate APP processing in mitochondria and assessed the possible mechanisms underlying H2S-mediated AD development. We treated neurons from APP/PS1 transgenic mice with a range of sodium hydrosulfide (NaHS) concentrations. NaHS attenuated APP processing and decreased Aβ production in mitochondria. Meanwhile, NaHS did not changed BACE-1 and ADAM10 (a disintegrin and metalloprotease 10) protein levels, but NaHS (30 μM) significantly increased the levels of presenilin 1(PS1), PEN-2, and NCT, as well as improved the γ-secretase activity, while NaHS (50 μM) exhibits the opposing effects. Furthermore, the intracellular ATP and the COX IV activity of APP/PS1 neurons were increased after 30 μM NaHS treatment, while the ROS level was decreased and the MMP was stabilized. The effect of NaHS differs from DAPT (a non-selective γ-secretase inhibitor), and it selectively inhibited γ-secretase in vitro, without interacting with Notch and modulating its cleavage. The results indicated that NaHS decreases Aβ accumulation in mitochondria by selectively inhibiting γ-secretase. Thus, we provide a mechanistic view of NaHS is a potential anti-AD drug candidate and it may decrease Aβ deposition in mitochondria by selectively inhibiting γ-secretase activity and therefore protecting the mitochondrial function during AD conditions.

Indexed as

Amyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesAnimalsCell SurvivalCerebral CortexHydrogen SulfideIsoenzymesMice, TransgenicMitochondriaNeuronsPresenilin-1Primary Cell CultureSulfidesAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesHydrogen SulfideIsoenzymesPresenilin-1presenilin 1, mousesodium bisulfideSulfidesAlzheimer’s disease (AD)Hydrogen sulfide (H2S)MitochondriaNotchγ-Secretase

Identifiers

PMID26708452
OpenAlexW2205369029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.